SynapDx Corporation Secures Investment From The Kraft Group

LEXINGTON, Mass.--(BUSINESS WIRE)--SynapDx Corporation today announced it has secured a significant investment from The Kraft Group. The funding will support the ongoing clinical development of SynapDx’s breakthrough blood-based autism spectrum disorder (ASD) diagnostic test, designed to help clinicians identify children with autism earlier than they do today. Conducting business in more than 90 countries with more than 5,000 employees worldwide, The Kraft Group, headquartered in Foxborough, Mass., is the holding company for the Kraft family’s various businesses, with interests in paper and packaging manufacturing, sports and entertainment, real estate development and a portfolio of private equity investments.